Enhancing Methylation Analysis for Biomarker Discovery and Clinical Applications

As rapid advancements in molecular profiling technologies and the development of sophisticated predictive algorithms fuel this fundamental shift in healthcare, the potential for precision medicine is becoming increasingly clear. But this is just the beginning.

In a significant advancement for epigenetic research, Renew Biotechnologies has partnered with Oxford Nanopore Technologies to develop Direct Whole Methylome Sequencing (dWMS). This innovative approach overcomes limitations of traditional bisulfite sequencing and methylation microarrays by eliminating DNA damage from harsh chemical treatments and sequencing biases from PCR amplification. As a result, dWMS offers comprehensive genome-wide coverage, capturing up to 98% of the 28.1 million CpG methylation sites in the human genome, and enables simultaneous detection of DNA sequence, methylation, and hydroxymethylation patterns.

The collaboration aims to accelerate breakthroughs in genomic and epigenomic analysis, driving innovation in both research and clinical applications. By integrating Oxford Nanopore's rapid, accessible sequencing technology with Renew's proprietary methylation assays, the partnership seeks to redefine standards in epigenetic research and revolutionize the field.

For a deeper understanding of this transformative technology and its implications for biomarker discovery and clinical applications, watch the full presentation from the American Society of Human Genetics Annual Meeting.